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Abstract: 
Context: A strategy for controlling pharmacy costs in managed care is to provide incentives for 
physicians to prescribe efficiently. Little is known about how the choice of method for assigning 
budgetary surpluses or deficits impacts individual physicians. 
Objective: To develop alternative statistical approaches for risk adjustment of pharmacy 
utilization at the physician level, and compare projected surpluses or deficits with those 
generated by traditional methods. 
Design: Use of two basic statistical modeling techniques: multivariable, fixed-effects, linear 
regression as the traditional approach, and mixed models as the alternative. Explanatory 
variables consisted of age, gender, and patient diagnoses. 
Setting: Two managed care populations in 1999, one from the Midwestern US in which all 
physicians were in a risk arrangement, the other from three Western States where two-thirds of 
physicians took risk. 
Main Outcome Measures: The range of projected surpluses or deficits for individual 
physicians, and the intra-class correlation coefficient (the proportion of variability in expenses 
attributable to differences among physicians). 
Results: The intra-class correlation coefficients were very small, 0.04 or less in both 
populations. However, the projected financial performance of individual physicians varied 
tremendously under the traditional approach, from a maximum deficit of$104,086 to a 
maximum surplus of$116,403. In comparison, an alternative approach projected a maximum 
deficit of$26,341 and a maximum surplus of$14,526 using the same data. 
Conclusions: In the two populations studied, traditional regression models led to substantial 
differences in surpluses and deficits among physicians, despite almost negligible statistical 
differences in physician performance. The alternative approaches generated considerably 
smaller surpluses or deficits, underscoring the practical implications and importance of the 
choice of method when individual physicians are at risk. 
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The Challenge of Assigning Surpluses or Deficits to Individual Physicians "At Risk" for 
Managed Care Pharmacy Expenses 
ABSTRACT 
Context. A strategy for controlling pharmacy costs in managed care is to provide incentives for 
physicians to prescribe efficiently. Little is known about how the choice of method for assigning 
budgetary surpluses or deficits impacts individual physicians. 
Objective. to develop alternative statistical approaches for risk adjustment of pharmacy 
utilization at the physician level, and compare projected surpluses or deficits with those 
generated by traditional methods. 
Design. Use of two basic statistical modeling techniques: multivariable, fixed-effects, linear 
regression as the traditional approach, and mixed models as the alternative. Explanatory 
variables consisted of age, gender, and patient diagnoses. 
Setting. Two managed care populations in 1999, one from the Midwestern U.S. in which all 
physicians were in a risk arrangement, the other from three Western States where two-thirds of 
physicians took risk. 
Main Outcome Measures. The range of projected surpluses or deficits for individual physicians, 
and the intra-class correlation coefficient (the proportion of variability in expenses attributable to 
differences among physicians). 
Results. The intra-class correlation coefficients were very small, 0.04 or less in both 
populations. However, the projected financial performance of individual physicians varied 
tremendously under the traditional approach, from a maximum deficit of $1 04,086 to a maximum 
surplus of $116,403. In comparison, an alternative approach projected a maximum deficit of 
$26,341 and a maximum surplus of $14,526 using the same data. 
Conclusions. In the two populations studied, traditional regression models led to substantial 
differences in surpluses and deficits among physicians, despite almost negligible statistical 
differences in physician performance. The alternative approaches generated considerably 
smaller surpluses or deficits, underscoring the practical implications and importance of the choice 
of method when individual physicians are at risk. 
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The Challenge of Assigning Surpluses or Deficits to Individual Physicians "At Risk" for 
Managed Care Pharmacy Expenses 
Introduction. A common strategy 1 to control rising pharmacy costs in managed care is to hold 
physicians financially responsible or "at risk" for these expenditures.2 If patient expenses fall 
below the target, physicians receive a bonus. If expenses exceed the target, physicians suffer the 
loss. A number of concerns arise if surpluses or deficits are allocated to individual physicians. 
There is an ethical concern if the dollars involved represent a significant portion of a physician's 
income. 3 There are also technical concerns regarding the validity of the methods used to 
calculate these incentives. 
Usually in managed care settings, physician "efficiency" is measured only indirectly, that is, as 
the ratio of the actual patient costs to their expected costs, 4 or alternatively, as the difference 
between the patients' expected and actual expenditures. 5 If either formulation is used to 
determine the financial incentive, then the magnitude of a physician's bonus or penalty will 
depend on how closely his or her patients' costs approximate their expected amounts. Because 
comprehensive criteria are not readily available for identifying what prescriptions individual 
patients should receive, a physician's expected costs are often based on those of the "average" 
physician, an example of a practiced-based norm. 6 Use of this type of norm presents two 
challenges: properly accounting for the illness burden of the patients, 7 and appropriate methods 
for the statistical comparison of physicians. 
Illness burden is addressed through risk adjustment. Although sophisticated methods have been 
used in studies of quality of care provided by hospitals 8 and physicians, 9 risk adjustment 
methods used in managed care settings are generally less developed. Sometimes no adjustment 
is performed, 10 or at best, multivariable linear regression models are used controlling for age, 
gender, and at times diagnostic information. 7• 11 ' 12 A common measure of how well the risk has 
been adjusted at the patient level is the proportion of the variability in expenses accounted for by 
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the explanatory variables, a quantity known as the R2• 13 The higher reported values for managed 
care pharmacy utilization have been in the 0.20 - 0.30 range. 12• 14• 15 The extent to which these 
low values reflect variability in physician prescribing habits and or inadequate risk adjustment is 
not known. 
Comparing physicians also presents statistical challenges, the financial consequences of which 
are not well understood either. Sometimes, researchers measure "efficiency" by including the 
"provider" as an explanatory variable in linear regression models. 16• 17 However, this may 
overstate the provider effect, particularly for physicians caring for small numbers of patients, 8• 9• 18 
and consequently exaggerate the surplus or deficit for an individual physician. Moreover, this 
technique does not distinguish between pure sampling variability and true inter-physician 
variability, the latter being an important aspect of the profiling process. 8 There are other 
concerns with using traditional regression methods to compare physicians. For example, such 
methods assume that each patient's costs are unrelated to those of every other patient, that is, 
patient costs are "statistically independent." However, this assumption presents a contradiction 
because patients served by a physician who systematically prescribes efficiently or inefficiently 
share, by definition, a common practice style. Failure to properly account for these clusters of 
patients is tantamount to assuming all physicians prescribe homogeneously. If an organization 
really believed all physicians prescribed the same, then there would be no need to compare 
physicians in the first place. This flaw also has some important implications for statistical 
inference. 
The major goal of this study is to derive physician-level surpluses or deficits by approaches that 
are more defensible from a methodological point of view than those based on traditional linear 
regression. The practical consequences of the choice of statistical method will be illustrated by 
comparing the physician-level surpluses or deficits generated by these different approaches. 
The key difference between the alternative and traditional approaches studied is the use of a 
statistical technique known as a "mixed" model. With this, heterogeneity in physician prescribing, 
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and hence clustering of patient costs by physician, is captured through the introduction of a 
random physician effect. The simplest approach assumes heterogeneity is reflected entirely by 
physician-level differences in the baseline cost for the "average" patient. This allows prescriber 
efficiency to be assessed more explicitly by partitioning the overall variability in prescribing costs 
into two components: random error and inter-physician variability. Our emphasis will be on the 
choice of statistical models rather than on the identification of the best risk-adjusting variables 
available, which would necessitate a separate study. Thus our analyses utilized a set of 
clinically-meaningful diagnostic categories which we developed for the public domain. 
Methods. We studied two distinct patient populations from different HMOs, referenced by 
geographical location within the United States. To simplify interpretation of the findings, the 
analyses were confined to patients 18 to 64 years old with total pharmacy expenditures under 
$20,000 per year, enrolled for at least 11 months of the year, and attended by primary care 
physicians with at least 10 HMO patients. This reduced variability in expenditures due to 
catastrophic conditions, differences between adults and children, enrollment times, or practitioner 
type. We also assumed that the organizations as a whole performed at their target levels. This 
implies "physician efficiency" is being assessed relative to the average physician within his or her 
organization, an appropriate point of view from the perspective of a managed care organization. 
Primary care physicians were defined as family physicians, internists, and pediatricians. 
Pharmacy expenditures were defined as the "ingredient costs", or contracted average wholesale 
price of the pharmaceuticals minus a network discount. As is common in profiling, 4• 19 costs were 
assigned to the designated primary care physician even if the prescriptions were written by 
others. 
The physicians of the "Midwestern" population belonged to a physician-hospital organization at 
risk for medical and pharmacy expenditures as previously reported. 20 The "Western" population 
was drawn from a three-State region HMO in which most physicians were independent 
practitioners. Approximately two-thirds of these physicians participated in a risk arrangement. 
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Initial analyses, and in particular variable selection, were periormed using 1996 data from the 
Midwest. Minor modifications to the list of explanatory variables were made subsequently, but 
the same models were used with 1998 and 1999 Midwestern data, and with 1999 Western data. 
The primary outcome of interest is the derived surplus or deficit at the physician level expressed 
in two forms, as absolute dollars and as a proportion of the actual expenditures of the panel of 
patients. These are reported in aggregate, that is, as the range of physician surpluses or deficits 
determined by the various methods. Of secondary interest is the extent of physician influence on 
pharmacy costs, measured here through the "intra-class correlation coefficient" (ICC). 9· 21 The 
ICC measures the proportion of variability in a patient's expenditures attributable to the physician 
effect. Values of ICC close to 1.0 indicate physician-level factors (eg. prescribing habits) explain 
most of the observed variability in patient pharmacy costs; values close to 0.0 indicate the 
opposite. 
All statistical analyses were periormed using SAS Version 6.12. 22 Two basic statistical modeling 
techniques were used. The first or traditional approach used fixed-effects, multivariable linear 
regression models, generated through SAS PROC REG. The second employed similar models but 
also included a random intercept term, a simple example of a mixed effects model, as generated 
through PROC MIXED. Given an arbitrary patient with covariates X, the traditional approach 
assumes the pharmacy costs for this type of patient are, on average, the same for every 
physician: 
predicted cost for physician i for a patient with covariates X= a + f(X), 
where a is an intercept term that represents the cost of the average patient and f(.) is some 
known function of the patient-level covariates X. Importantly, nei1her a nor f(.) depend on the 
specific patient or physician under consideration. With this approach, a physician's surplus or 
deficit is calculated as the sum of the actual expenditures of the patients minus the sum of their 
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predicted costs. Thus, a positive difference yields a deficit owed by the physician and a negative 
difference a surplus. 
In contrast, the mixed effects model assumes 
predicted cost for physician i for a patient with covariates X= a+ b(i) + f(X). 
Here, a and f(.) are as above, and b(i) represents a physician-specific contribution to the per-
patient cost independent from the specific patient under consideration. This model assumes the 
unobserved deviations b(i) are normally distributed with mean zero and constant variance. 
Theoretically, the parameter a is the same in both the fixed and mixed effects regression models, 
and represents the cost of the average patient in the entire managed care organization. Because 
we have assumed the organization performs at its target level, the expected contribution of any 
physician to this average cost is therefore equal to zero. Physician heterogeneity is incorporated 
by allowing the model intercept to be physician-specific, which in practical terms means we allow 
a given physician's actual contribution to patient costs to deviate from the expected contribution 
of zero. The "empirical best linear unbiased predictor" (EBLUP) of the deviations b(i) constitute 
model-derived, direct estimates of each physician's per patient contribution to cost (hereafter, 
the "physician effect"). An estimated surplus or deficit for a given physician may then be derived 
by multiplying his or her EBLUP by the number of his or her patients. From an organizational 
perspective, a negative value constitutes a surplus owed to an "efficient" physician, and positive 
value a deficit owed by an "inefficient" physician. The use of the EBLUP effectively "shrinks" the 
estimated surplus or deficit towards zero, relative to what it would have been if computed under 
the traditional approach. The amount of shrinkage for a given physician decreases as one or both 
of the ICC and patient panel size increases. 9 We refer to this alternative approach as the 
"intercept method", and compare this to the traditional fixed-effects approach referenced as 
"linear regression". 
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Because the notion of an "efficient" physician is inexact, and point estimates of the surplus (or 
deficit) are subject to sampling variability, we also present an example of a decision rule that 
could be used to modify the EBLUP further in the calculation of a specific incentive. We refer to 
this as" the confidence interval rule". We first compute an estimate of the standard deviation 
(SD) of each physician's estimated surplus or deficit (SURDEF), then subsequently a crude 
confidence interval of the form SURDEF +1- SD. The SD calculation reflects two sources of 
variation: that due to inter-physician heterogeneity and that due to sampling variability. 
Mathematical details underlying the SD computation are available as supplemental material. 
Financial risk is subsequently determined as follows. If the confidence interval contains zero, 
then the physician's surplus or deficit is set to zero. If SURDEF- SO exceeds zero, then this 
amount is taken as the deficit owed by the physician. Similarly, if SURDEF + SD is less than 
zero, then this is taken to be the surplus owed to the physician. This decision rule sets a limit on 
the amount of inter-physician heterogeneity that will be tolerated, accounting for the uncertainty 
in the estimated surplus/deficit. For a given patient panel, an efficient physician is defined as one 
who operates within +1- 1 SD of the "ideal" physician whose discretionary contribution to patient 
costs are exactly zero. Generally, this rule leads to surplus and deficits smaller than those 
produced by the "intercept" method, the extent being governed by the magnitude of the SD. 
We also studied the impact of using both the intercept method and its confidence interval 
application for separate pharmacy categories. We defined 28 mutually-exclusive pharmaceutical 
groups based on their American Hospital Formulary Service classification number. 23 Categories 
were defined to be clinically relevant, for example, "antibacterials", "antihistamines", "Gl", 
"cardiovascular", and "antidepressants". Details are available as supplemental material. The total 
cost for each patient is correspondingly broken down into 28 mutually exclusive parts, with each 
component of total cost modeled separately as described above. This approach yields 28 
EBLUP-derived surplus (or deficit) estimates per physician, which are then summed to produce 
an overall surplus or deficit estimate. The "28 models" approach makes significantly less 
restrictive assumptions regarding the relationship between patient covariates and total pharmacy 
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costs, and allows a physician's influence on costs to differ across the categories. Confidence 
intervals are also constructed for each category, as previously described. 
In all, 5 basic approaches were compared: "traditional linear regression", "intercept method 
single model", "intercept method 28 models", "confidence interval rule single model", and 
"confidence interval rule 28 models". For all five approaches, explanatory variables consisted of 
patient age and gender at a minimum, with patient diagnoses utilized as indicated. Because 
diagnoses were not assigned to particular prescriptions, they were obtained from the medical 
care claims of the patients and merged with their pharmacy data. The Clinical Classifications for 
Health Policy version 2 (now know as the Clinical Classifications Software) 24• 25 was used to 
group ICD9 diagnoses into 260 categories, 12 which were in turn collapsed into 37 groups of 
clinically similar conditions, examples of which are "infections", "diabetes", "affective disorders", 
and "hypertension ". Further details are available as supplemental material. 
The baseline scenarios capped pharmacy costs per category at $2500, that is, costs higher than 
$2500 were assigned the value of $2500, whether costs were examined with single or with 28 
models. This level accounted for approximately 95% of pharmacy expenditures, and modulated 
the influence of the higher cost patients. Sensitivity analyses were performed by varying the level 
of the cap for pharmacy costs within each category, and also the minimum physician panel size. 
Results. Characteristics of the two study populations are shown in Table One. Despite similar 
age and gender compositions, the groups differed more than two-fold in per-patient pharmacy 
expenditures. Costs were highly skewed in both groups. When costs were capped at a 
maximum of $750 per pharmacy category, the most expensive patient incurred$ 6,836 in the 
Midwestern population and $5,703 in the Western population (Table 2). When the ceiling of 
costs was raised to $20,000 per pharmacy category, the most costly patient incurred $19,782 in 
the Midwestern population, and $18,914 in the Western. 
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With traditional linear regressions for the Midwestern population, the adjusted R2 ranged from 
0.10 (costs per pharmacy category capped at $750) to 0.06 (costs capped at $20,000), 
controlling for patient age and gender (results not displayed in tables). When patient diagnoses 
were also considered, the adjusted R2 improved to 0.39 and 0.30 respectively. The regression 
models performed less well in the Western population, where the corresponding measures were 
0.06 and 0.03 controlling for age and gender, and 0.26 and 0.20 using diagnoses. 
Only a small proportion of the overall variability in both populations could be attributed to the 
physician (random) effect, expressed as the intra-class correlation coefficient (Table 2), as 
derived from the mixed models. In the Midwestern population, the coefficients ranged from a 
high of 0.018 to a low of 0.002, depending on the modeling technique, level of capped 
expenditures and use of diagnoses. There was relatively more variability among physicians in the 
Western population, where the intra-class correlation coefficient ranged from 0.042 to 0.003. 
Estimates of the 209 Midwest physicians' EBLUPs, (their specific contributions to patient costs), 
are shown in Figure 1 and expressed as dollars per patient (single mixed model, costs per 
category capped at $2500). The one standard deviation confidence intervals surrounding these 
EBLUPs are very broad, with an average width of $112. 
The projected financial performance of the physicians varied greatly depending on the modeling 
method used (Figure 2). Only one scenario from the Midwest population in 1999 is shown (per 
category costs capped at $2500), but the pattern was similar in both populations using varying 
levels of capped costs. The outer dark bars encompass the entire range of physicians. The 
inner lighter bars represent the range between the fifth and ninety-fifth percentile of physicians, 
that is, the middle 90%. The largest individual surpluses or deficits were projected from the 
standard regression models, particularly those controlling only for patient age and gender. With 
this scenario, individual physician performance ranged from a deficit of $104,086 to a surplus of 
$116,403 in the Midwest population, and a deficit of $89,964 to a surplus of $83,199 in the 
Western. This range was compressed somewhat with the "intercept method", especially when 
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the 28 models employing diagnoses were considered. As expected, the smallest surpluses or 
deficits were projected using the "confidence interval rule" for each of the 28 pharmacy 
categories. Here, the maximum physician deficit in the Midwestern population was $26,341 and 
the maximum surplus $14,526. The corresponding figures in the Western population were 
$24,773 and $5,494. The difference in estimates for the Midwest population compared to the 
comparable "intercept" method is appreciable, and largely reflects the substantial variability 
observed in Figure 1 . 
The differences among the various methods appear more striking when the surpluses or deficits 
are expressed as proportions of the actual expenditures of the patient panels (Figure 3). The 
largest proportional surpluses or deficits were generated through linear regression models 
controlling only for patient .age and gender. One physician was projected to owe 60% of his 
patient's expenditures, while another would receive a bonus nearly 6 times the pharmacy costs of 
his patients. In the West, the physician with the worse deficit would have to pay back 80% of his 
patient's expenditures, while a peer would receive a surplus 97 times what his or her patients 
spent. The smallest range in performance was that determined by the confidence interval rule for 
each of the 28 pharmacy categories. In the Midwest, the physician with the proportionally largest 
deficit would owe 1 0% of his patient's expenditures with this method, while the physician with the 
largest surplus would receive 19% of the pharmacy costs of his panel. The corresponding figures 
in the West were 16% and 15%, respectively. 
At the organizational level, it is important for budgetary reconciliation that the physician-level 
surpluses or deficits sum to zero. Such agreement is assured if a traditional linear regression 
model is used. However, this did not occur under the various mixed models we fit, primarily 
because of the way in which the physician-level surpluses (or deficits) are derived. With the use 
of the "intercept" method, there was a projected net aggregated physician surplus in the Midwest 
of between 0.2 % and 1.8 % of the total pharmacy expenditures, depending on the level of 
capped costs, models and covariates considered. In the West there was not a consistent 
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pattern, with net surpluses or net deficits projected depending on the scenario used, however 
these were within 3% of the total pharmacy costs. Using the confidence interval allocation rule, 
there was a projected net summed physician deficit ranging between 0.4% and 1.0% of total 
pharmacy expenditures in the Midwest, and between 0.4% and 2.2% in the West, indicating 
money would be owed by the aggregated physicians to the managed care organizations. 
A sensitivity analysis was performed (Figure 4) to determine whether the wide range in physician 
performance was due to high cost patients and small physician panel sizes. Consequently, a 
restricted sub-population of patients was studied whose costs were capped at a maximum of 
$750 per pharmacy category, and who were assigned to physicians who had at least 200 patients 
per panel. Under these conditions, the range in physician performance based on linear 
regression tightened considerably over that of the baseline scenario shown in Figure 2. 
However, the range in physician performance determined by the confidence interval rule, 28 
mixed models, did not change substantially from the baseline scenario. This suggested the latter 
approach was less sensitive to the inclusion of high cost patients and small physician panel sizes. 
Comment. We developed and studied some alternatives to traditional linear regression for 
measuring and rewarding physician prescribing efficiency. The magnitude of the projected 
physician-level surpluses or deficits varied greatly depending on the statistical modeling method 
used. We found variability among physician prescribing was small relative to other sources of 
variability in the data, a finding consistent with that reported recently regarding the management 
of diabetes. 9 Although the findings were similar in two populations differing more than two-fold in 
pharmacy expenditures, they might not be generalizable to others. Our methodological 
considerations would continue to remain applicable, however. 
We believe that the major criterion for selecting a preferred approach is methodological validity. 
Explicit control of an individual physician's profit or loss is secondary. As indicated in the 
Introduction, using linear regression to derive expected costs for individual physicians rests on 
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questionable, possibly even contradictory, foundations. The use of mixed models has a more 
defensible methodological basis because they allow for the systematic aspect of a physician's 
practice, a specific objective of profiling. A useful way to think about the key difference between 
the traditional and mixed regression methods is as follows. Under the traditional approach, the 
"residual cost", or actual- predicted cost, is assumed to be entirely due to the physician effect, 
with no allowance for random {e.g., yearly) variability in prescribing costs for patients of a given 
type. In contrast, the mixed model assumes this residual further consists of two components: a 
systematic contribution due to the physician, and random variability. The EBLUP estimates the 
former, and its use at least acknowledges that there is an important difference between these two 
types of contributions for the purposes of determining financial responsibility. 
Once the physician's contribution to costs has been quantified, some mechanism is needed for 
generating a fair incentive. The confidence interval allocation rule appears to be a reasonable 
approach. It defines an efficient physician as one whose likely contribution to costs is within 1 
standard deviation of the expected contribution of zero. Statistically, its construction 
acknowledges that point estimates of the physician effect are still subject to sampling variability 
(see Figure 1), thus reducing the possibility of disproportionate rewards or penalties by the 
vagaries of chance. Methodologically, it allows for some inter -physician heterogeneity in the 
definition of "efficiency", and for some uncertainty regarding physician-level risk factors that are 
neither related to quality of care nor under their direct control. This allocation rule is certainly not 
the only way in which one could incorporate the various sources of variability into the incentive 
process. Nevertheless, it balances methodological, practical, and statistical concerns in a 
reasonably straightforward manner. 
There are some limitations with this study that should be acknowledged. Our diagnostic 
categories might not be the optimal set of explanatory variables. However, any improvement 
over these would be expected to decrease the range of surpluses or deficits even further. There 
are also some limitations connected to our use of mixed regression models. For example, we 
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assume the variation in physician practice patterns is completely captured by the inclusion of a 
random intercept term, and that the variation in this term reflects only "controllable" variation in 
practice styles. Both of these assumptions represent substantial oversimplifications. Our use of 
28 different models, hence 28 random intercept terms for the various cost categories, may 
partially offset these drawbacks. These assumptions could be relaxed with the incorporation of 
additional data on factors thought to influence physician practice style but having no explicit 
connection to pharmacy costs. Such data are presently unavailable. Another limitation is that 
physician performance continues to be defined in terms of how the average physician prescribes 
rather than by criteria on how they should prescribe. However, comprehensive criteria-based 
guidelines linked directly to organizational expenditures are presently unavailable. In the 
meantime, studying pharmaceutical categories separately, as done with the 28 models, permits 
some flexibility in the assessment process. Because the categories were clinically defined, some 
type of weighting, or a mixed reimbursement scheme such as that proposed by Schokkaert 26 
could be developed in the future. For example, physicians could assume a greater share of risk 
for antihistamine utilization than for cardiovascular drugs. A final, more practical limitation is that 
of budgetary reconciliation. As indicated, the sum of the physicians' surpluses and deficits 
obtained under the various mixed model approaches generally do not net out exactly to zero. 
Although the imbalance represented a very small percentage of the pharmacy expenditures in all 
cases, an organization would still need a mechanism for the reconciliation process, particularly if 
it exceeded its budget. We view this concern as being more administrative than methodological, 
and consequently will not attempt to make further recommendations here. 
Physicians within each of the two organizations practiced similarly on the most part to other 
physicians within their organization. If physician inefficiency were the sole factor responsible for 
the difference in costs between the Midwestern and Western population, then most physicians in 
the Midwestern population were prescribing inefficiently. Thus, if organizations wish to control 
their pharmacy costs, we suggest the focus be directed away from penalizing its outlier 
physicians, 27 towards identifying and addressing the factors responsible for the shared high-cost 
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culture. 9• 28• 29 Such explanations might include unmeasured case mix differences, administrative 
structures, benefit designs, co-pay influence, 2 physician supply, 29 activity of pharmaceutical 
detailing and other cultural factors. 30 Unfortunately, sufficient data were not available to us to 
examine these influences at this time. 
A fair allocation of surpluses or deficits to individual physicians is not an easy task, nor can it be 
done without error. The methodological concerns regarding the traditional approaches appear to 
have practical consequences. Given the continued rise in pharmaceutical costs 31 and the real 
potential for large profits or losses, 32 those currently under risk arrangements may wish to 
scrutinize how their own surplus or deficit is being calculated. 
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Table 1. Demographics of the populations in the analyses 
Mid-Western Western 
Number of adult covered lives with 52,913 70,979 
continuous enrollment in 1999 
Mean age in years 41.5 41.1 
(sd 12.5) (sd 11. 7) 
%Female 52.6% 53.7% 
Mean Ingredient Costs $37.63 $ 17.87 
per member month* (sd 83.05) (sd 49.37) 
Median Ingredient Costs $6.43 $2.22 
per member month* 
% members with no pharmacy 27.0% 35.9% 
costs in year 
Number of physicians with 209 477 
minimum panel of 10 patients 
Mean number of patients per 253 149 
physician (sd 264) (sd 197) 
Median number of patients per 172 70 
physician 
*maximum patient costs $20,000 per year 
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Table 2. Proportion of overall variability attributed to physician random effect. Minimum 
Physician Panel Size of 1 0. 
1999 Mid-Western Population 
Level of Maximum Intra-Class Correlation 
capped costs patient Coefficient 
per pharmacy 
Age-Gender Diagnoses and pharmacy expenditures 
category per year Co variates Age-Gender Co variates 
1 Mixed Model $750 $6,836 0.018 0.016 
$2,500 $11,067 0.014 0.012 
$20,000 $19,782 0.010 0.009 
28 Mixed Models $750 $6,836 0.006 0.005 
$2500 $11,067 0.004 0.004 
$20,000 $19,782 0.003 0.002 
1999 Western Population 
Level of Maximum Intra-Class Correlation 
capped costs patient Coefficient 
per pharmacy 
Age-Gender Diagnoses and pharmacy expenditures 
category per year Co variates Age-Gender 
Co variates 
1 Mixed Model $750 $ 5,703 0.042 0.029 
$2,500 $10,033 0.035 0.024 
$20,000 $18,914 0.025 0.017 
28 Mixed Models $750 $5,703 0.007 0.006 
$2500 $10,033 0.005 0.004 
$20,000 $18,914 0.004 0.003 
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Figure 1. Individual physicians' empirical best linear unbiased predictors (EBLUPs). 
Midwestern population of physicians (n = 209), patient costs per pharmacy category capped at 
$2500. This shows the estimate of each of the physicians' effect on his or her patients' costs, 
surrounded by a one standard deviation confidence interval. 
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Figure 2. Range of individual physicians' surplus or deficits projected by the various 
methods. Midwestern population of physicians (n = 209), patient costs per pharmacy category 
capped at $2500. Negative numbers represent surpluses to physicians, positive numbers are 
deficits. The dark outer bars encompass the entire range of physician performance. The inner 
lighter bars represent the range of the middle 90% of physicians. 
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Figure 3. Range of individual physicians' surpluses or deficits projected by the various 
methods, expressed as a proportion of their patients' expenditures. Midwestern population 
of physicians (n = 209), patient costs per pharmacy category capped at $2500. Negative numbers 
represent surpluses to physicians, positive numbers are deficits. The dark outer bars encompass 
the entire range of physician performance. The inner lighter bars represent the range of the 
middle 90% of physicians. 
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Figure 4. Range of individual physicians' surpluses or deficits, expressed as a proportion 
of their patients' expenditures. Restricted scenario where the maximum costs per 
category were capped at $750, and each physician had a minimum of 200 patients in his or 
panel. Negative numbers represent surpluses to physicians, positive numbers are deficits. The 
dark outer bars encompass the entire range of physician performance. The inner lighter bars 
represent the range of the middle 90% of physicians. 
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